- Home
- FLYW vs SLNO Comparison
FLYW vs SLNO Comparison
Compare FLYW & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYW
- SLNO
- Stock Information
- Founded
- FLYW 2009
- SLNO 1999
- Country
- FLYW United States
- SLNO United States
- Employees
- FLYW N/A
- SLNO N/A
- Industry
- FLYW Computer Software: Prepackaged Software
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- FLYW Technology
- SLNO Health Care
- Exchange
- FLYW Nasdaq
- SLNO Nasdaq
- Market Cap
- FLYW 2.2B
- SLNO 1.9B
- IPO Year
- FLYW 2021
- SLNO 2014
- Fundamental
- Price
- FLYW $22.93
- SLNO $54.63
- Analyst Decision
- FLYW Strong Buy
- SLNO Strong Buy
- Analyst Count
- FLYW 13
- SLNO 7
- Target Price
- FLYW $24.85
- SLNO $69.86
- AVG Volume (30 Days)
- FLYW 1.6M
- SLNO 504.7K
- Earning Date
- FLYW 11-07-2024
- SLNO 11-06-2024
- Dividend Yield
- FLYW N/A
- SLNO N/A
- EPS Growth
- FLYW N/A
- SLNO N/A
- EPS
- FLYW 0.16
- SLNO N/A
- Revenue
- FLYW $475,139,000.00
- SLNO N/A
- Revenue This Year
- FLYW $22.83
- SLNO N/A
- Revenue Next Year
- FLYW $25.27
- SLNO N/A
- P/E Ratio
- FLYW $141.05
- SLNO N/A
- Revenue Growth
- FLYW 26.50
- SLNO N/A
- 52 Week Low
- FLYW $15.19
- SLNO $26.38
- 52 Week High
- FLYW $31.54
- SLNO $59.75
- Technical
- Relative Strength Index (RSI)
- FLYW 74.26
- SLNO 51.30
- Support Level
- FLYW $21.51
- SLNO $50.69
- Resistance Level
- FLYW $23.13
- SLNO $59.75
- Average True Range (ATR)
- FLYW 1.06
- SLNO 2.47
- MACD
- FLYW 0.25
- SLNO -0.48
- Stochastic Oscillator
- FLYW 95.21
- SLNO 43.47
About FLYW Flywire Corporation Voting
Flywire Corp provides a secure payment platform, offering its clients a streamlined process to receive reconciled domestic and international payments more cost-effectively and efficiently. The company's solutions are built on three core elements namely a payments platform; a proprietary global payment network and vertical-specific software backed by its deep industry expertise. Geographically, the majority of revenue is from the Americas.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.